Results 21 to 30 of about 8,174 (197)

Efficacy of daclatasvir plus peginterferon alfa and ribavirin for patients with chronic hepatitis C genotype 4 infection

Bangladesh Journal of Pharmacology, 2017
Clinical trials evaluating the safety and efficacy of daclatasvir for chronic hepatitis C virus (HCV) genotype 4 infection are scarce and yet with small sample sizes.
Hussien Ahmed, Abdelrahman Ibrahim Abushouk, Mohamed Gadelkarim, Arwa Mohamed, Mohamed Gabr, Ahmed Negida   +5 more
doaj   +1 more source

Daclatasvir and asunaprevir combination therapy for patients with chronic hepatitis C virus genotype 1b infection in real world [PDF]

The Korean Journal of Internal Medicine, 2019
Background/Aims Previous studies have reported a high rate of sustained virologic response (SVR) and a low rate of serious adverse events with the use of daclatasvir (DCV) and asunaprevir (ASV) combination therapy. We evaluated the efficacy and safety of
Jae Young Oh, Byung Seok Kim, Chang Hyeong Lee, Jeong Eun Song, Heon Ju Lee, Jung Gil Park, Jae Seok Hwang, Woo Jin Chung, Byoung Kuk Jang, Young Oh Kweon, Won Young Tak, Soo Young Park, Se Young Jang, Jeong Ill Suh, Sang Gyu Kwak   +14 more
doaj   +1 more source

Rapid reductions in prices for generic sofosbuvir and daclatasvir to treat hepatitis C

Journal of Virus Eradication, 2016
Objectives: Novel treatments for hepatitis C demonstrate high cure rates, but current high prices can be a barrier to rapid global treatment scale-up. Generic competition can rapidly lower drug prices.
Andrew Hill, Bryony Simmons, Dzintars Gotham, Joseph Fortunak   +3 more
doaj   +1 more source

Identification of resistance mutations to DAA's against Hepatitis C Virus in infected subjects in Mexico

Annals of Hepatology, 2022
Introduction and Objectives: Death due to liver damage caused by hepatitis C virus (HCV), this agent represents one of the most frequent health threats in Mexico.
K López-Riojas, KA Galán-Huerta, AF Ruiz-Higareda, L Muñoz-Espinosa, P Cordero-Pérez, D Arellanos-Soto, S Lozano-Sepúlveda, AM Rivas-Estilla   +7 more
doaj   +1 more source

Long-term outcomes of direct acting antivirals in post-transplant advanced hepatitis C virus recurrence and fibrosing cholestatic hepatitis. [PDF]

, 2017
Long-term functional outcomes of sofosbuvir-based antiviral treatment were evaluated in a cohort study involving 16 Italian centres within the international compassionate use programme for post-transplant hepatitis C virus (HCV) recurrence. Seventy-three
Burra, Patrizia, Romano, Antonietta, Russo, Francesco Paolo   +2 more
core   +1 more source

Validated Reversed-Phase Liquid Chromatographic Method with Gradient Elution for Simultaneous Determination of the Antiviral Agents: Sofosbuvir, Ledipasvir, Daclatasvir, and Simeprevir in Their Dosage Forms

Molecules, 2020
A simple, rapid, sensitive, and precise reversed-phase liquid chromatographic method was developed and validated for the simultaneous determination of four direct-acting antivirals, sofosbuvir (SF), ledipasvir (LD), declatasvir (DC), and simeprevir (SM),
Essam Ezzeldin, Nisreen F. Abo-Talib, Marwa H. Tammam, Yousif A. Asiri, Abd El-Galil E. Amr, Abdulrahman A. Almehizia   +5 more
doaj   +1 more source

The new paradigm of hepatitis C therapy: integration of oral therapies into best practices. [PDF]

, 2013
Emerging data indicate that all-oral antiviral treatments for chronic hepatitis C virus (HCV) will become a reality in the near future. In replacing interferon-based therapies, all-oral regimens are expected to be more tolerable, more effective, shorter ...
Afdhal, NH, Castera, L, Church, DR, Dee, L, Graham, C, Jacobson, IM, Litwin, AH, Mehta, SH, Muir, A, New Paradigm of HCV Therapy Meeting Participants, Poynard, T, Razavi, H, Schooley, RT, Sulkowski, MS, Talal, AH, Thomas, DL, Ward, JW, Zeuzem, S   +17 more
core   +2 more sources

Hepatitis C virus resistance to the new direct-acting antivirals [PDF]

, 2016
Introduction: The treatment of hepatitis C virus (HCV) infection has dramatically improved in recent years with the widespread use of interferon-free combination regimens.
Esposito, Isabella, Soriano, Vicente, Trinks, Julieta   +2 more
core   +1 more source

Liver transplantation for viral hepatitis in 2015 [PDF]

, 2016
Liver transplantation (LT) is a life-saving treatment for patients with end-stage liver disease and for patients with liver cell cancer related to liver disease.
Bortoluzzi, Ilaria, Burra, Patrizia, Ferrarese, Alberto, Gambato, Martina, Germani, Giacomo, Nadal, Elena, Russo, FRANCESCO PAOLO, Senzolo, Marco, Zanetto, Alberto   +8 more
core   +1 more source

Daclatasvir Plus Asunaprevir for the Treatment of Patients with Hepatitis C Virus Genotype 1b Infection: Real-World Efficacy, Changes in Liver Stiffness and Fibrosis Markers, and Safety

Gut and Liver, 2018
Background/AimsThe treatment with daclatasvir plus asunaprevir (DCV+ASV) is associated with potent antiviral effects in patients with genotype 1b hepatitis C virus (HCV) infection.
Hye Won Lee, Se Rim Oh, Dong Yun Kim, Yechan Jeong, Seungtaek Kim, Beom Kyung Kim, Seung Up Kim, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Jun Yong Park   +10 more
doaj   +1 more source